Wire · operational-macro
StockWatch: Liquidia Rebounds After Settling Legal Wrangle with United Therapeutics
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 October 2026 · Fusion42 review
Liquidia settled a multi-year legal dispute with United Therapeutics, agreeing to pay $380.7 million and remove a PH-ILD indication from its product Yutrepia, while continuing its PAH market and development of new formulations. The settlement removed regulatory risks, allowing Liquidia to rebound in the stock market and focus on growth, including leveraging FDA fast track for Raynaud’s phenomenon.
This Wire brief sits within Fusion42's coverage of Biotech, and 4 sources have reported it between 30 Sep 2026 and 18 Oct 2026.
◆ ◆ The Wire takeaway
Your work in pulmonary arterial hypertension just gained clearer commercial runway with legal risks cleared and FDA fast track intact. You can now refocus on sales growth and pipeline expansion knowing the PH-ILD market pullback is not as damaging as feared.
◆ Coverage
4 sources · first reported 30 Sep 2026 · latest 18 Oct 2026
◆ Related on Wire
◆ Topics